SCHEMBL1553626

SCHEMBL1553626

CCCCc1nc(-c2ccc(C(F)(F)F)cc2)sc1C(OC)c1ccc(C(=O)OC)c(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 2/20 0.39
HSP90AA1 P07900 1/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
PPARD Q03181 8/20 0.38
PPARA Q07869 5/20 0.38
RARA P10276 1/20 0.36
RARB P10826 1/20 0.36
RARG P13631 1/20 0.36
ALDH1A1 P00352 2/20 0.36
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
KLK7 P49862 1/20 0.35
FFAR1 O14842 2/20 0.35
PPARG P37231 1/20 0.34
CFTR P13569 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1554170 0.92 NPC1 (0.43) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL1553627 0.79 PPARD (0.40) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL1387061 0.79 NOTUM (0.39) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL3532780 0.79 PPARG (0.36) PPARDPPARAPPARG
SCHEMBL1553829 0.76 MAPT (0.56) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL1553871 0.72 PPARD (0.48) MAPTPPARDPPARAFFAR1PPARG
SCHEMBL1554129 0.71 ALDH1A1 (0.48) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL1554172 0.70 NPC1 (0.44) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL4485086 0.69 MAPT (0.70) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL14015121 0.69 KDM4E (0.53) MAPTMEN1KMT2AKDM4EHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735303-B1 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF AVENTIS PHARMA INC (US) 2011-04-27 EP disclosed
US-7576109-B2 1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof AVENTIS PHARMACEUTICALS INC. (US) 2009-08-18 US disclosed
US-20070060626-A1 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF AVENTIS PHARMACEUTICALS INC. (US) 2007-03-15 US disclosed
EP-1735303-A2 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF Aventis Pharmaceuticals, Inc. (US) 2006-12-27 EP disclosed
WO-2005097762-A2 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AVENTIS PHARMACEUTICALS INC. (US) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060626-A1 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF PPARD, PPARA, PPARG MAPT 742/4885MEN1 4804/4885KMT2A 4520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.